MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00392-022-02126-8

Медицинская библиотека · Clinical research in cardiology : official journal of the German Cardiac Society · 2022

Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications.

Nuzzi Vincenzo, Cannatà Antonio, Pellicori Pierpaolo, Manca Paolo, Stolfo Davide, Gregorio Caterina, Barbati Giulia, Bromage Daniel I, McDonagh Theresa, Cleland John G F, Merlo Marco, Sinagra Gianfranco

СтатьяПеревод в очереди

Аннотация

BACKGROUND

For patients with heart failure, prescription of loop diuretics (LD) and of higher doses are associated with an adverse prognosis. We investigated LD dose trajectories and their associations with outcomes in patients with dilated cardiomyopathy (DCM).

METHODS

Associations between outcomes and both furosemide-equivalent dose (FED) at enrolment and change in FED in the subsequent 24 months were evaluated. According to FED trajectory, patients were classified as (i) dose↑ (FED increase by ≥ 50% or newly initiated); (ii) dose↓ (FED decrease by ≥ 50%); (iii) stable dose (change in FED by < 50%); and (iv) never-users. The primary outcome was all-cause-death/heart transplantation/ventricular-assist-device/heart failure hospitalization. The secondary outcome was all-cause-death/heart transplantation/ventricular-assist-device.

RESULTS

Of 1,131 patients enrolled, 738 (65%) were prescribed LD at baseline. Baseline FED was independently associated with outcome (HR per 20 mg increase: 1.12 [95% CI 1.04-1.22], p = 0.003). Of the 908 with information on FED within 24 months from enrolment, 31% were never-users; 29% were dose↓; 26% were stable dose and 14% were dose↑. In adjusted models, compared to never-users, stable dose had a higher risk of the primary outcome (HR 2.42 [95% CI 1.19-4.93], p = 0.015), while dose↑ had the worst prognosis (HR 2.76 [95% CI 1.27-6.03], p = 0.011). Results were similar for the secondary outcome. Compared to patients who remained on LD, discontinuation of LD (143, 24%) was associated with an improved outcome (HR 0.43 [95% CI 0.28-0.65], p < 0.001).

CONCLUSIONS

In patients with DCM, LD use and increasing FED are powerful markers of adverse outcomes. Patients who never receive LD have an excellent prognosis. Among 1131 DCM patients 65% received loop diuretics at enrolment (upper left side). The bar chart on the upper right side shows the categorization in never-users/ dose↓/stable dose/ dose↑ over 24 months of follow-up. At the bottom is reported on the left side of each panel (observation period) the trajectory of LD dose in the four groups (left panel) and in patients who have their LD suspended vs those who continue LD (right panel) in the first two years. On the right side of each panel is shown the incidence of primary outcomes during the subsequent follow-up in the subgroups (outcome assessment).

Для цитирования: Nuzzi Vincenzo, Cannatà Antonio, Pellicori Pierpaolo, Manca Paolo, Stolfo Davide, Gregorio Caterina, Barbati Giulia, Bromage Daniel I, McDonagh Theresa, Cleland John G F, Merlo Marco, Sinagra Gianfranco. Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications.. Clinical research in cardiology : official journal of the German Cardiac Society. 2022. DOI: 10.1007/s00392-022-02126-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.